Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
CNS Therapeutics
Advertisement
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
AI Drug Discovery Deal Expands CNS Pipeline Value
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
Lupin Launches Topiramate ER Capsules in United States
MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 — Global pharmaceutical company Lupin Limited announced the U.S. launch of...
Contineum Secures $90M Funding to Advance CNS Drug Pipeline
BOSTON, December 12, 2025 — Contineum Therapeutics, Inc. announced the pricing of an upsized $90.0 million public offering of...
Advertisements
FDA Clears Path Forward for Vanda’s Motion-Sickness Drug Development
WASHINGTON, D.C., December 4, 2025 — The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold...
FDA Clears Jupiter Neurosciences’ JOTROL™ for Phase 2a Parkinson’s Trial
JUPITER, Florida, November 5, 2025 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company, announced that the U.S....
Relmada Secures $100 Million to Accelerate CNS and Oncology Pipeline Expansion
CORAL GABLES, Fla., November 4, 2025 — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biopharmaceutical company focused on developing...
Precision NeuroMed Earns FDA Orphan Drug Status for GBM Therapy
REDWOOD CITY, Calif., Oct. 7, 2025 — Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing next-generation drug delivery technologies...
Advertisement
